27 Январь,2003 | Acute Mania - New bipolar disorder indication sought for Seroquel
AstraZeneca has announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for Seroquel for the treatment of acute mania associated with bipolar disorder . Drug Week via NewsEdge Corporation : AstraZeneca has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Seroquel (quetiapine) for the treatment of acute mania associated with bipolar disorder (manic-depressive illness). The application to the FDA follows the completion of a comprehensive bipolar disorder clinical trial program undertaken by AstraZeneca to examine the efficacy and tolerability of Seroquel in this important disease area. The program has delivered strong and positive results in both the monotherapy and adjunctive therapy studies, which confirm Seroquel to be an ideal first line agent in the treatment of acute mania associated with bipolar disorder. "Seroquel is destined to be an important treatment option for clinicians treating bipolar disorder," commented Gary Sachs from Harvard Medical School, Boston, and lead investigator on the studies. "Treatment compliance in bipolar disorder is particularly critical since patients may lead full and productive lives when stable while a relapse in symptoms can cause real difficulties. The ability of Seroquel to improve the symptoms of the disease while keeping side effects to a minimum, may improve quality of life and ultimately lead to greater compliance with medication, offering real benefits to clinicians, patients and families." The trial program consisted of 4 double-blind, randomized trials, involving almost 1000 patients in 28 countries. The trials assessed the effectiveness and safety of Seroquel as both monotherapy and adjunctive therapy with mood stabilizer in the treatment of acute mania associated with bipolar disorder. Results from 1 of the adjunct trials were presented at the 3rd European Stanley Foundation Conference in Bipolar Disorder, in Germany. The results from this 3-week trial showed that Seroquel (average dose in responders of 580 mg/day), in combination with a standard mood stabilizing medication (lithium or divalproex), is significantly more effective than mood stabilizers alone in treating acute mania and is also well tolerated. Specifically, the results showed that patients treated with Seroquel benefited from: * A significantly greater improvement from baseline in their Young Mania Rating Scale (YMRS) total scores at day 21 compared with patients taking mood stabilizers alone (-13.76 and -9.93 respectively, p=0.021). * A significantly greater improvement from baseline in their Clinical Global Impression Bipolar (CGI-BP) Severity of Illness scores at endpoint compared to patients taking mood stabilizer alone (-1.38 and -0.78 respectively, p=0.001). * An incidence of EPS no different from placebo across the full dose range. The results from the remaining monotherapy studies will be presented at major psychiatry conferences in 2003. "We are very pleased with the results of the trial program and are extremely optimistic about the future for Seroquel. Seroquel is a truly unique compound and its profile is ideal for the treatment of bipolar disorder," commented Geoff Birkett, global vice president, CNS, Pain, and Infection. "Success in the market is driven by the impact on patients and our vision to introduce therapies that truly change patients' lives for the better. With its expanded indication range, Seroquel will continue to help patients and is the cornerstone of our rapidly growing CNS business." Seroquel is manufactured by AstraZeneca and is currently approved in over 75 markets. Seroquel combines broad-based efficacy in the treatment of positive, negative, cognitive, and affective symptoms of schizophrenia, while offering excellent tolerability. Seroquel is associated with an incidence of EPS and prolactin elevation no different to placebo across the full dosage range, a favorable weight profile, and no clinically important effects on QT interval. To date, over 4 million people have been treated with Seroquel worldwide. This article was prepared by Drug Week editors from staff and other reports. <> << Copyright ©2003 NewsRx.com >>
26 Январь,2003 | Anti-depression drug still in use despite warnings
The number of patients addicted to a drug treating depression has been increasing steadily despite the company warning the government that it should be banned. Mainichi Daily News via NewsEdge Corporation : 01/26/2003 The number of patients addicted to a drug treating depression has been increasing steadily despite the company warning the government that it should be banned. The drug, whose brand name is Ritalin, is dubbed by drug addicts as a "hospital upper" because it has similar effects to amphetamines and hallucinogenics. Ritalin has been on sale in more than 60 countries for treating oversleeping, but it is only used for light cases of depression in Japan. After experts voiced doubts about its effectiveness for mild states of depression, the Health Ministry began reviewing it in 1995. At that time, Novartis Pharma K.K., the company that markets Ritalin, told the ministry that the use of the drug on slightly depressed patients should be banned Officials of the company even added that at least one user committed suicide after taking the drug and becoming mentally unstable. "Users of the drug risk becoming addicted, and there are other effective drugs," one official of Novartis Pharma said. "So we thought that the drug had already finished its role as a treatment for slightly depressed patients." But the ministry only changed the description of suitable Ritalin users from "slight cases of depression" to "depression patients after other anti-depression drugs prove ineffective" in 1998. Now experts say that the government must take countermeasures as an increasing number of Ritalin users have become addicted or suffered mental and physical trouble. It is also alleged that some people pretend to be in a state of depression to receive Ritalin when seeing doctors because they believe they can get a kick by taking the drug. A 28-year-old woman said she had been diagnosed by mental doctors as being a depression patient and began taking three Ritalin pills a day. "Three pills a day soon lost their effect on me, so I visited several hospitals to receive the drug and took 20 pills a day," she said. "Then my heart beat sped up and I sometimes I used to hear strange noises, like I was hallucinating." She then visited the Akagi-kohgen Hospital, which exclusively looks after alcohol and drug abusers. Michio Takeyama, director of the Gunma Prefecture hospital, said that doctors should be aware of the risk of Ritalin users becoming addicted. "They have to be more careful about giving the drug to patients," Takeyama said. A 31-year-old man sought help at the Self-Support Service, a non-profit organization in Tokyo's Koto-ku that gives consultation to drug addicts, after he took a two-week prescription of Ritalin pills in just three days. "I couldn't help myself because I knew I could get high without being arrested," he said. An official of the Health, Labor and Welfare Ministry supervising the drug industry said that it still approves the use of Ritalin on depression patients because they have reports of its efficacy. Copyright 2003. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire http://www.novartis.com <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>
25 Январь,2003 | When hyperactivity in kids ceases to be normal
Tina Arceo-Dumlao 01/25/2003 WHEN celebrity Kris Aquino came out in the open and said that her son, Joshua, was suffering from Attention Deficit Hyperactivity Disorder , many Filipinos realized that children they used to label as sobrang malikot were actually sick and in need of special medical treatment. Philippine Daily Inquirer via NewsEdge Corporation : Tina Arceo-Dumlao 01/25/2003 WHEN celebrity Kris Aquino came out in the open and said that her son, Joshua, was suffering from Attention Deficit Hyperactivity Disorder (ADHD), many Filipinos realized that children they used to label as sobrang malikot (too fidgety) were actually sick and in need of special medical treatment. But even with a greater awareness of ADHD, studies show that less than one percent of Filipino children suffering from it are actually diagnosed of the ailment. Dr. Peter Joare, a member of the medical faculty of the University of Edinburgh and one of the leading authorities on ADHD, said global figures are just as bad, with only between 3 and 10 percent of children worldwide affected by ADHD getting diagnosed. One of the reasons behind the low diagnosis rate is the lack of awareness of the disease and the fact that many of the symptoms can be dismissed as simple bad behavior and are thus left untreated. More boys affected ADHD is a psychiatric disorder characterized by inattention, hyperactivity and impulsivity that occur more frequently or severely compared to other children their age, thus affecting their performance in school or in social gatherings. It was first diagnosed 100 years ago by George Still, an Englishman, who described it as a "disorder of moral control." ADHD occurs more frequently in boys than in girls, with male to female ratios ranging from 4:1 to 9:1. It occurs across cultures as well as socioeconomic levels. Symptoms occur before the age of 7. Three types There are three main types: inattentive, hyperactive/impulsive and a combination of the two. Those considered primarily inattentive have difficulty following instructions, avoid or dislike tasks that require sustained mental effort, are easily distracted, do not appear to listen and have difficulty with organization. The hyperactive/impulsive types fidget with hands or feet or squirm in their chair, have difficulty engaging in activities quietly, act as if driven by a motor, talk excessively, have difficulty waiting or taking turns and interrupt or intrude upon others. The combined type shows symptoms of both types. In an interview with the Inquirer during his recent visit to Manila, Joare said some children suffering from ADHD outgrow these symptoms but as much as 50 to 60 percent of untreated children carry the disease up to adulthood. "If left untreated, most ADHD sufferers would grow up to be at greater risk to substance abuse and then to road accidents because they are either inattentive or hyperactive/impulsive. Their sense of danger is also impaired," Joare said. What causes ADHD? The cause of ADHD is still unknown but a majority of research works on the disease suggest that it is caused by neurological and genetic factors. Joare explained that children are normally born with some degree of inattention, hyperactivity and impulsivity but as their brain develops, controls are put in place to inhibit these behaviors to promote learning and motivation. Joare said the chemicals that help the brain inhibit these behaviors are imbalanced in children and adults with ADHD. Drugs like Concerta of Johnson & Johnson help correct this chemical imbalance. Unlike other drugs, Concerta is taken only once a day and is effective for about 12 hours. Drugs, however, are not enough to cure ADHD. Joare said medicine should be combined with behavioral modification therapy to help a child overcome the debilitating effects of ADHD. Copyright 2003. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>
25 Январь,2003 | .DELTA.9 Tetrahydrocannabinol (.DELTA.9 THC) solution metered dose inhaler (Assignee -- Virginia Commonwealth University)
Abstract: The present invention provides therapeutic formulations for solutions of .DELTA..sup.9 -tetrahydrocannabinol to be delivered by metered dose inhalers. The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of .DELTA.. U.S. Patents via NewsEdge Corporation : Abstract: The present invention provides therapeutic formulations for solutions of .DELTA..sup.9 -tetrahydrocannabinol (.DELTA..sup.9 THC) to be delivered by metered dose inhalers. The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of .DELTA..sup.9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy; muscle spasticity; pain; anorexia associated with AIDS wasting syndrome; epilepsy; glaucoma; bronchial asthma; and mood disorders. Ex Claim Text: A pharmaceutical composition consisting essentially of 1,1,1,2,3,3,3-heptafluoropropane (HFA 227), .DELTA..sup.9 -tetrahydrocannabinol, and up to 15 percent by weight of an organic solvent, said .DELTA..sup.9 -tetrahydrocannabinol and said organic solvent being dissolved in said HFA 227 to form a stable composition, wherein said .DELTA..sup.9 -tetrahydrocannabinol is present in said composition in concentrations ranging from 0.147% w/w (.+-.0.008) to 5.940% w/w (.+-.0.191). Patent Number: 6509005 Issue Date: 2003 01 21 If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787. Inventor(s): Peart, Joanne Byron, Peter R. Lichtman, Aron H. Martin, Billy R. << Copyright ©2003 MicroPatent >>
23 Январь,2003 | Finding Cures for Manic Depression/ Prechter Fund Awards $500,000 To Researchers at Massachusetts General Hospital
DETROIT, Jan. 23 /PRNewswire/ -- Waltraud "Wally" Prechter, founder and president of the Heinz C. PR via NewsEdge Corporation : DETROIT, Jan. 23 /PRNewswire/ -- Waltraud "Wally" Prechter, founder and president of the Heinz C. Prechter Fund for Manic Depression, announced today a $500,000 grant to researchers at Massachusetts General Hospital (MGH) to help find cures for manic depression, also known as bipolar disorder. The funds will be used to establish the "Prechter Center for the Study of Genetics of Pediatric Bipolar Disorders." MGH serves as a teaching hospital for Harvard Medical School and was ranked the best hospital for psychiatry in the United States in U.S. World and News Report of 2001. Dr. Joseph Biederman, chief of MGH's Pediatric Psychopharmacology Research Program and professor of psychiatry at Harvard Medical School, heads the research team. The team will receive $500,000 over a two-year period to conduct research of children suffering from manic depression. Dr. Biederman's team will launch one of the largest long-term genetics studies in pediatric bipolar disorder by analyzing over 1,600 DNA samples from children afflicted by manic depression and their related family members. The researchers set out to identify the genes responsible for manic depression. In addition, they hope to determine which genes affect how children respond to specific medications. "We are excited to partner with one of the leading bipolar research teams in the nation," said Prechter. "Dr. Biederman and his colleagues will be instrumental in identifying the genetic underpinnings of the insidious hereditary disease of manic depression. We are confident that Dr. Biederman's research will lead to better diagnostic tools, improved treatment options and -- ultimately -- cures for manic depression." "We are honored that the Prechter Fund would make its first major gift to us," said Biederman. "We fully share the vision of the Prechter family to help develop cures for manic depression. Through the Prechter Center we honor the family of a man who made a tremendous difference in this world -- and continues to do so." Prechter established the non-profit Heinz C. Prechter Fund for Manic Depression in memory of her late husband to advance breakthrough medical research to help develop cures for bipolar disorder. Industrialist Heinz Prechter introduced the sunroof to America and built his one-man enterprise into a global group of companies. He suffered from intermittent bouts of manic depression for most of his adult life and fell victim to suicide at the age of 59 in July 2001. Since then, Prechter has emerged as one of the most outspoken and effective mental health advocates in the United States. She provided testimony before Congress to increase the federal funding for bipolar disorder research and was appointed by President George W. Bush to the New Freedom Commission on Mental Health to help improve the mental health care system in the United States. Moreover, the Prechter Fund raised over $1.25 million at its first gala dinner in October 2002 turning the event into the largest single fund-raising event for manic depression in U.S. history. Manic depression affects an estimated 2.7 million adult Americans. As debilitating as blindness or paraplegia, manic depression adds significantly to the overall economic burden of mental disorders of $170 billion a year in health care expenditures and economic loss due to lost productivity, absenteeism and premature death. An estimated 730,000 Americans attempt suicide every year with close to 30,000 of them completing the horrific act, that is one suicide every 17 minutes. Nearly 70 percent of suicides are depression related. SOURCE Heinz C. Prechter Fund for Manic Depression -0- 01/23/2003 /CONTACT: Stephan Koller, Executive Director of Heinz C. Prechter Fund for Manic Depression, +1-734-246-0056; Susan McGreevey of Massachusetts General Hospital, +1-617-724-2764/ CO: Heinz C. Prechter Fund for Manic Depression; Massachusetts General ST: Michigan, Massachusetts IN: MTC HEA SU: NPT TH-ML -- DETH019 -- 7480 01/23/2003 13:29 EST http://www.prnewswire.com <> << Copyright ©2003 PR Newswire >>
22 Январь,2003 | Пополнение в разделе Пособия
В разделе пособия для врачей размещена лекция "Сосудистые психозы" канд.мед.наук доц. кафедры психиатрии ЦОЛИУВ (ныне РМАПО) Видмановой Л.Н. В работе излагаются вопросы клиники, дифференциальной диагностики и терапии психических расстройств при сосудистых заболеваниях головного мозга.
22 Январь,2003 | Researchers Discover Anxiety and Aggression Gene in Mice - /CAUTION -- ADVANCE FOR RELEASE AT 6 A.M. EST THURSDAY, JAN. 23/
/ADVANCE/ CLEVELAND, Jan. 22 /PRNewswire/ -- Researchers report finding a gene that is essential for normal levels of anxiety and aggression. PR via NewsEdge Corporation : /ADVANCE/ CLEVELAND, Jan. 22 /PRNewswire/ -- Researchers report finding a gene that is essential for normal levels of anxiety and aggression. Calling it the Pet-1 gene, researchers at the Case Western Reserve University School of Medicine Department of Neurosciences say that when this gene is removed or "knocked out" in a mouse, aggression and anxiety in adults are greatly elevated compared to a control (also called wild type) mouse. Other neurologic functions, such as motor coordination, feeding, and locomotor activity, do not appear altered in the knockout mouse. Anxiety and aggression are normal and important behaviors that allow individuals to respond appropriately to threats or cope with a challenging environment. However, it is clear that uncontrollable or excessive anxiety and aggression can be counterproductive. "The Pet-1 knockout mouse we've made is very likely to represent a new model for gaining a greater understanding of human disorders characterized by heightened anxiety and violence," says Evan Deneris, Ph.D., principal investigator of the study and a neuroscientist at CWRU. The study is published in the Jan. 23 issue of the science journal Neuron. Previously, Deneris' lab showed that in the brain, Pet-1 is active only in serotonin nerve cells or neurons, a relatively small number of cells (among the trillions of neurons in a human brain, only a few hundred thousand produce serotonin) that profoundly affect emotions. Serotonin is a chemical that acts as a messenger or neurotransmitter allowing neurons to communicate with one another in the brain and spinal cord. It is important for ensuring an appropriate level of anxiety and aggression. Defective serotonin neurons have been linked to excessive anxiety, impulsive violence, and depression in humans. Antidepressant drugs such as Prozac and Zoloft work by increasing serotonin activity and are highly effective at treating many of these disorders. But it is unknown why some people have dysfunctional serotonin neurons and whether this can be caused by defects in genes that are normally required for their early development. "We have now shown that Pet-1 is required specifically for fetal development of serotonin neurons," says Deneris. In mice missing this gene, most serotonin neurons fail to be generated in the fetus and the ones that remain are defective. This leads to very low serotonin levels throughout the developing brain, which in turn results in altered behavior in adults. "This is the first gene shown to impact adult emotional behavior through specific control of fetal serotonin neuron development." Deneris and his colleagues employed sensitive tests of aggression and anxiety to compare the behavior of the knockout mice to wild type mice. One such aggression test measures a mouse's response time to an intruder mouse entering its territory. The Pet-1 knockout mice attacked intruders much more quickly and more often than wild type mice. In fact, knockout mice often would not engage in normal exploratory behavior directed toward the intruder before attacking it. Excessive anxiety-like behavior was evident in another test, measuring the amount of time a mouse spends in open unprotected areas of a test chamber compared to closed protected areas. Unlike normal mice, which will enter and explore an unprotected portion of the test chamber, the Pet-1 knockout mice avoided this area all together, indicating abnormal anxiety-like behavior. The human and mouse serotonin systems share many anatomical and functional features, and the same Pet-1 gene is present in the human genome. Therefore, Deneris' discovery creates the first animal model for gaining a greater understanding of the causes of abnormal anxiety and aggression brought about through defective early serotonin neuron development. Deneris also sees this knockout mouse being used as a model for screening new drugs that can treat both aggression and anxiety. "If in fact particular genetic variants of Pet-1 are associated with excessive anxiety or violent activity in humans, then tests to detect these variants might be useful for early diagnosis of people who may be at risk for developing these abnormal behaviors," Deneris says. His lab plans more studies in mice to see how the gene affects sleep-wake patterns, learning and memory, and sexual behavior - all functions controlled in part by serotonin. Lead authors on the study are Timothy J. Hendricks, and Dmitry V. Fyodorov, who were graduate students in Deneris's lab at the time of the study. Other authors are, from CWRU: Lauren J. Wegman, Nadia B. Lelutiu, Elizabeth A. Pehek, Ph.D., Bryan Yamamoto, Ph.D., and Jerry Silver, Ph.D.; and, from Baylor College of Medicine, Edwin J. Weeber, Ph.D., and J. David Sweatt, Ph.D. SOURCE Case Western Reserve University School of Medicine -0- 01/23/2003/0600 /NOTE TO EDITORS: Videos displaying aggressive behavior of Pet-1 knockout mice can be viewed at http://neurowww.cwru.edu/faculty/deneris.shtml; click Movies Link./ /CONTACT: George Stamatis, Director, Public Affairs of Case Western Reserve University School of Medicine, +1-216-368-3635/ /Web site: http://www.cwru.edu/ CO: Case Western Reserve University School of Medicine ST: Ohio IN: HEA MTC SU: BG-LA -- CLW024 -- 5790 01/22/2003 14:38 EST http://www.prnewswire.com <> << Copyright ©2003 PR Newswire >>
20 Январь,2003 | Диссертации:
на заседании диссертационного совета НЦПЗ РАМН состоялась защита кандидатской диссертации
28 Декабрь,2002 | Острые эндогенные психозы - Пападопулос Т.Ф.
Острые эндогенные психозы - Пападопулос Т.Ф.
26 Декабрь,2002 | HUMAN SCHIZOPHRENIA GENE
Abstract: Nucleic acids comprising the neuregulin 1 gene and encoding NRG1 polypeptides are disclosed. European Patents via NewsEdge Corporation : Abstract: Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Pub. No.: EP 1265999 Appl. Data: EP 01913147 2001 02 28 If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787. Applicant: Decode Genetics EHF. << Copyright ©2002 MicroPatent >>
| Главная | Структура центра | История НЦПЗ | Совет молодых ученых | Костромские школы молодых ученых | Новости | Профсоюз | Правовые документы | Вакансии | О сайте | Научная работа | Научные отделы и лаборатории | Публикации сотрудников | Диссертационный совет | Авторефераты диссертаций | Музей НЦПЗ | Для научных сотрудников НЦПЗ | Центр коллективного пользования «Терапевтический лекарственный мониторинг» | Образовательная деятельность | Ординатура | Аспирантура | Дополнительное профессиональное образование | Студенческий научный кружок | Нормативные документы | Платные образовательные услуги | Информация для обучающихся в ординатуре и аспирантуре | Лечебный процесс | Клинические отделения | Условия и порядок стационирования | Прейскурант платных медицинских услуг | Перечень заболеваний | Отзывы о работе клиники | Клиника (фотогалерея) | Библиотека | Научная литература для специалистов | Материалы конференций | Авторефераты диссертаций | Пособия для врачей | Психометрические шкалы | Болезнь и творчество | Галерея | Журнал «Психиатрия» | Перечень тематических журналов, рекомендованных ВАК | Перечень тематических журналов в международных БД | РИНЦ | Russian Science Citation Index (RSCI) | Полезные ссылки | Журнал «Психиатрия» | Неспециалистам | Контакты